GLP-1 receptor agonists have been shown to be effective in the treatment of NAFLD patients with diabetes (6), but there is lack of evidence for its efficacy and mechanism of action in non-diabetic NAFLD patients (7). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.